Loading…
Lobbying Spend
—
Filings
20
Firms Hired
1
Active Period
2022–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Combating Illicit Xylazine Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 1266
ALERT Communities Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 1561
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 2004
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: HR 2214
Health Care PRICE Transparency Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: HR267
Improving Seniors’ Timely Access to Care Act of 2025
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 3514
Telehealth Modernization Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: HR 5081
To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage.
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 5243
FY2027 Appropriations, ACA Subsidy Sunset, Funding for HHS/NIH, Medicare & Medicaid, Reductions of personnel at HHS, Research Funding, PACT Act with VA - funding for community care - reimbursements from VA Tracking and outreach to delegation: S.3345 - PBM Price Transparency and Accountabity Act HR 5256 - 340B Access Act HR 6240 Rural Hospital Closure Relief Act - Tracking Grid by state to compare what programs are activated Tracking OMB Order on political appointees reviewing discretionary grant applications.
Client expense: — · Firm income: $24,000
Matched citations: HR 5256
Rural Hospital Fairness Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: HR5821
Fight Illicit Pill Presses Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 5880
Rural Hospital Closure Relief Act of 2025
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
FY2027 Appropriations, ACA Subsidy Sunset, Funding for HHS/NIH, Medicare & Medicaid, Reductions of personnel at HHS, Research Funding, PACT Act with VA - funding for community care - reimbursements from VA Tracking and outreach to delegation: S.3345 - PBM Price Transparency and Accountabity Act HR 5256 - 340B Access Act HR 6240 Rural Hospital Closure Relief Act - Tracking Grid by state to compare what programs are activated Tracking OMB Order on political appointees reviewing discretionary grant applications.
Client expense: — · Firm income: $24,000
Matched citations: HR 6240
Rural Residency Planning and Development Act of 2025
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: HR 6468
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 7184
STOP Nitazenes Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 7970
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 7994
Stop Pills That Kill Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 8005
To amend Public Health Service Act to require community health centers to provide behavioral and mental health and substance use disorder services, and for other purposes.
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 8201
Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 9389
Prices on the Wall Act of 2026
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 9390
Lower Costs, More Transparency Act of 2026
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 9393
Transparency in Medicare Advantage Steering Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 9395
Prior Authorization Accountability Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 9396
Premium Transparency Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: H.R. 9397
Telehealth Modernization Act
2026 · second_quarter · Firm: CAROL G HOLLADAY & ASSOCIATES
Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution
Client expense: — · Firm income: $24,000
Matched citations: S. 2709
Source: Senate LDA